抄録
Background: Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods: A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated. Results: Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04). Conclusion: SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 1204-1213 |
| ページ数 | 10 |
| ジャーナル | International Journal of Clinical Oncology |
| 巻 | 24 |
| 発行部数 | 10 |
| DOI | |
| 出版物ステータス | 出版済み - 10 1 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Hematology
- Oncology
これを引用
Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response : a pooled analysis of a multicenter clinical trial (KSCC 1605-A). / Sasaki, Shun; Oki, Eiji; Saeki, Hiroshi; Shimose, Takayuki; Sakamoto, Sanae; Hu, Qingjiang; Kudo, Kensuke; Tsuda, Yasuo; Nakashima, Yuichiro; Andou, Kouji; Akagi, Yoshito; Kakeji, Yoshihiro; Baba, Hideo; Maehara, Yoshihiko.
：: International Journal of Clinical Oncology, 巻 24, 番号 10, 01.10.2019, p. 1204-1213.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response
T2 - a pooled analysis of a multicenter clinical trial (KSCC 1605-A)
AU - Sasaki, Shun
AU - Oki, Eiji
AU - Saeki, Hiroshi
AU - Shimose, Takayuki
AU - Sakamoto, Sanae
AU - Hu, Qingjiang
AU - Kudo, Kensuke
AU - Tsuda, Yasuo
AU - Nakashima, Yuichiro
AU - Andou, Kouji
AU - Akagi, Yoshito
AU - Kakeji, Yoshihiro
AU - Baba, Hideo
AU - Maehara, Yoshihiko
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Background: Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods: A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated. Results: Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04). Conclusion: SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.
AB - Background: Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods: A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated. Results: Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04). Conclusion: SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85065325729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065325729&partnerID=8YFLogxK
U2 - 10.1007/s10147-019-01460-8
DO - 10.1007/s10147-019-01460-8
M3 - Article
AN - SCOPUS:85065325729
VL - 24
SP - 1204
EP - 1213
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 10
ER -